Not sure if anyone has posted this or not….what is interesting about this study is that the results have garnered world wide attention with a similar participant size as the brilacidin study.
There's room for multiple therapeutics and I think any recognition in this direction and away from the vaccine revenue stream is positive attention for IPIX.
News 
Market Data 
Discover 
